The in vitro studies have already demonstrated the anti-tumor action of NKG2D-DAP10-CD3ζ-CAR-NK cells against osteosarcoma cell lines, pancreatic cancer, and breast cancer. This evidence concerns the gene KLRK1 and familial pancreatic carcinoma.